Daridorexant (for PTSD)
Post-Traumatic Stress Disorder
Clinical StudySupporting US DOD-sponsored clinical study
Key Facts
Indication
Post-Traumatic Stress Disorder
Phase
Clinical Study
Status
Supporting US DOD-sponsored clinical study
Company
About Idorsia
Idorsia is a public Swiss biotech company that emerged from the demerger of Actelion following its acquisition by Johnson & Johnson in 2017. It has built a balanced portfolio with one commercial product (QUVIVIQ for insomnia) and several late-stage clinical assets, including TRYVIO/JERAYGO for resistant hypertension. The company's strategy focuses on unlocking the value of its commercial product, expanding strategic partnerships, advancing its differentiated pipeline, and maintaining financial discipline.
View full company profileTherapeutic Areas
Other Post-Traumatic Stress Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Psilocybin-assisted Therapy | Incannex Healthcare | Phase 2 |